In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

World Health Organization Says No To Delayed Disclosure Of Clinical Trials

This article was originally published in The Gray Sheet

Executive Summary

The World Health Organization has decided that the public's need for transparency in clinical trials trumps industry concerns that early disclosure of certain information could undercut a company's competitive advantage

You may also be interested in...



Public Registration Of Device Trials Increases 10-Fold In Two Years

Registration of medical device trials on a government Web site increased more than 10-fold in the past two years, and legislation moving through Congress is likely to expand that activity even further

Notified Body Expert Akra Calls For Special Taskforce Measures To Oversee New COVID-19 Products

With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.

UsernamePublicRestriction

Register

MT023608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel